Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background: The aim of this study was to compare and summarize the lipid-altering effects of combination therapy with ezetimibe and statins (E/S) and a double dose of statin (D/S) monotherapy on patients with hypercholesterolemia. Methods: We conducted search on 2 medical databases, PubMed and EMBASE to identify all relevant studies. A meta-analysis was performed to clarify the efficacy in the two groups. Only double-blind Randomized controlled study (RCTs) of efficacy evaluation in the two groups with ezetimibe and statins and a double dose of statin in participants with hypercholesterolemia that examined low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC) and high-density lipoprotein (HDL) were included. Two reviewers extracted data from all primary studies independently. The primary data were the level of LDL-C, TC and HDL-C concentrations at the end point and are expressed as mean and standard deviation (SD). Results: A total of 11 double-blind, active or placebo-controlled studies with 1926 hypercholesterolemia adults randomized to ezetimibe 10 mg added to ongoing statins (N = 994) or statin titration (doubling) (N = 932) were pooled for the global meta-analysis. The effect size between treatment groups within individual studies was assessed by weighted mean difference (MD) using a random- or fixed-effect model. The result showed that the participants in E/S group get obvious lower LDL-C [MD = -13.14 mg/dL, 95%CI (−16.83, -9.44), p = 0.00001] and TC concentration [MD = -23.79 mg/dL, 95%CI (−38.65, -8.93), p = 0.002] from baseline to follow-up, comparing to the D/S group. Besides, no significant between-group differences were observed for concentrations of HDL-C [MD = 0.46 mg/dL, 95%CI (− 1.14, 2.06), p = 0.57]. According to subgroup analysis, the combination of ezetimibe and atorvastatin (10 mg) [MD = -16.98 mg/dL, p < 0 .0001] or simvastatin (20 mg) [MD = -17.35 mg/dL, p < 0 .0001] showed stronger ability of reducing LDL-C than combination of ezetimibe and rosuvastatin (10 mg) [MD = -9.29 mg/dL, p = 0.05]. The efficacy of short-term (endpoint time between 6 to 16 week) and long-term (52 week) treatment in the LDL-C between two groups did not show significant differences. Besides, only participants from Asia treated with combination therapy were associated with a significant lower LDL-C concentration [MD = -14.7 mg/dL, p < 0 .0001]. Conclusions: The addition of ezetimibe to statin appears to be more effective on reducing LDL-C and TC concentrations than doubling the statin dose. Moreover, the ability to reduce cholesterol levels of combinations therapy with ezetimibe and different statins or to participants from different geographic location may vary, based on this meta-analysis, while more samples are needed to verify.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Meta-analysis of the change in LDL-C between groups [mg/dL]. Forest plot showing the effect of combined therapy with ezetimibe and statin versus double-dose statin only on plasma biomarkers of LDL-C; LDL-C, low-density lipoprotein cholesterol](https://figures.cochat.ai/paper-figures/811081acb6504081a727ae8252f050c1/efficacy-of-combination-therapy-with-ezetimibe-and-statins-versus-a-double-dose-figure-2.jpg)
![Fig. 3 Meta-analysis of the change in TC between groups [mg/dL]. Forest plot showing the effect of combined therapy with ezetimibe and statin versus double-dose statin only on plasma biomarkers of TC; TC, total cholesterol](https://figures.cochat.ai/paper-figures/85ef54793b5149d394d8efb5c8ce7b21/efficacy-of-combination-therapy-with-ezetimibe-and-statins-versus-a-double-dose-figure-3.jpg)
![Fig. 4 Meta-analysis of the change in HDL-C between groups [mg/dL]. Forest plot showing the effect of combined therapy with ezetimibe and statin versus double-dose statin only on plasma biomarkers of HDL-C; HDL-C, high-density lipoprotein cholesterol](https://figures.cochat.ai/paper-figures/df643f4465424628a557a10770816644/efficacy-of-combination-therapy-with-ezetimibe-and-statins-versus-a-double-dose-figure-4.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ezetimibe’s safety and efficacy has been confirmed in multiple meta-analyses [61, 66–70].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [69]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Operating characteristics of a rank correlation test for publication bias
Begg, C. B., & Mazumdar, M. (1994) · Biometrics · doi:10.2307/2533446 · Cited by 16,955
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Prescribing Personalized Nutrition for Cardiovascular Health: Are We Ready?
Juma, S., Imrhan, V., Vijayagopal, P., & Prasad, C. (2014) · Lifestyle Genomics · doi:10.1159/000370213 · Cited by 1,891
Prepared by: British Cardiac Society, B. H. S. (2005) · Heart · doi:10.1136/hrt.2005.079988 · Cited by 1,216
The Role of Ethnicity in Variability in Response to Drugs: Focus on Clinical Pharmacology Studies
Yasuda, S., Zhang, L., & Huang, S.-M. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.141 · Cited by 393
Cited by
Metabolism of tissue macrophages in homeostasis and pathology
Wculek, S. K., Dunphy, G., Heras-Murillo, I., Mastrangelo, A., & Sancho, D. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00791-9 · Cited by 501
Plasma Free Fatty Acid Concentration as a Modifiable Risk Factor for Metabolic Disease
Henderson, G. C. (2021) · Nutrients · doi:10.3390/nu13082590 · Cited by 152
Ashrafian, F., Raftar, S. K. A., Lari, A., Shahryari, A., Abdollahiyan, S., Moradi, H. R., Masoumi, M., Davari, M., Khatami, S., Omrani, M. D., et al. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01709-w · Cited by 151
Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention
Michaeli, D. T., Michaeli, J. C., Albers, S., Boch, T., & Michaeli, T. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00594-5 · Cited by 109
Pranata, R., Huang, I., Irvan, I., Lim, M. A., & Vania, R. (2021) · Endocrine · doi:10.1007/s12020-021-02780-4 · Cited by 81
Metadata
- Authors
- Yu, M., Liang, C., Kong, Q., Wang, Y., & Li, M.
- Affiliations
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Army Medical University (CN)
- Corresponding author
- Wang, Yihan
- Venue
- Lipids in Health and Disease
- Published
- 2020-01-04
- Volume
- 19
- Issue
- 1
- Pages
- 1-1
- ISSN
- 1476-511X (ISSN-L)
- PMC
- PMC6942418
- OpenAlex
- W3001476701
- Semantic Scholar
- fa53a67b8aafd761a6b260cfad1560c92deca2c7
- Cited by
- 107
- References
- 28
- Citations by year
- 2026: 6 · 2025: 19 · 2024: 15 · 2023: 21 · 2022: 18 · 2021: 25 · 2020: 3
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Lipids in Health and Disease (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
- Keywords
- ezetimibe, statins, hypercholesterolemia, combination lipid-lowering therapy, LDL cholesterol, total cholesterol, HDL cholesterol, atorvastatin, simvastatin, rosuvastatin, lipid-lowering efficacy
- MeSH terms
- Ezetimibe, Aged, Cholesterol, Drug Combinations, Female, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Randomized Controlled Trials as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. https://app.cochat.ai/papers/10.1186/s12944-019-1182-5
- The paper
- Yu, M., Liang, C., Kong, Q., Wang, Y., & Li, M. (2020). Efficacy of combination therapy with ezetimibe and statins versus a double dose of statin monotherapy in participants with hypercholesterolemia: a meta-analysis of literature. Lipids in Health and Disease. https://doi.org/10.1186/s12944-019-1182-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.